英特集团(000411) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥6,847,281,141.76, an increase of 3.29% compared to the same period last year[3] - Net profit attributable to shareholders was ¥42,384,065.59, reflecting a growth of 21.13% year-on-year[3] - The basic earnings per share (EPS) was ¥0.1703, up by 21.09% from the previous year[3] - The company's total revenue for the current period reached CNY 19.92 billion, compared to CNY 18.49 billion in the previous period, indicating a year-over-year increase of about 7.7%[24] - The company reported a net profit of CNY 1.06 billion, an increase from CNY 0.94 billion, representing a growth of approximately 12.9%[23] - The net profit for Q3 2021 was CNY 314,663,860.80, an increase of 20.3% compared to CNY 261,578,660.46 in Q3 2020[26] - The operating profit for the quarter reached CNY 429,785,396.35, compared to CNY 359,762,588.78 in the same quarter last year, reflecting a growth of 19.4%[26] - The total comprehensive income for the period was CNY 314,598,153.90, compared to CNY 246,692,289.96 in the same period last year, indicating a growth of 27.5%[27] - The company reported a total profit of CNY 418,362,515.16 for the quarter, an increase of 15.1% from CNY 363,759,715.85 in Q3 2020[26] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥13,204,617,227.03, representing a 17.37% increase from the end of the previous year[3] - As of September 30, 2021, the total assets of Zhejiang Yinte Group Co., Ltd. amounted to CNY 13.20 billion, an increase from CNY 11.25 billion at the end of 2020, representing a growth of approximately 17.3%[21] - The total liabilities increased to CNY 9.66 billion from CNY 8.04 billion, reflecting a rise of approximately 20.2%[22] - Total current assets amounted to CNY 10,041,349,747.70, reflecting a decrease of CNY 23,195,229.61 compared to the previous period[32] - Total current liabilities were CNY 7,453,646,649.78, remaining unchanged from the previous period[34] - Total non-current liabilities increased to CNY 590,773,840.54, reflecting an increase of CNY 121,752,203.51[34] - Total equity of the company reached CNY 3.55 billion, up from CNY 3.21 billion, indicating an increase of approximately 10.6%[23] Cash Flow - The company’s cash flow from operating activities showed a net outflow of ¥499,598,231.62[3] - The net cash flow from operating activities was -499,598,231.62 yuan, a significant decrease compared to -323,253,522.16 yuan in the previous period, primarily due to reduced government support for pandemic-related purchases[11] - Cash flow from financing activities increased by 31.55% to 3,579,261,989.68 yuan, driven by higher cash received from borrowings[12] - The cash flow from financing activities generated a net inflow of CNY 427,154,431.37, compared to CNY 144,343,371.23 in the same period last year[29] Receivables and Financing - Accounts receivable increased by 30.18% to ¥6,532,368,395.48, primarily due to higher receivables from hospital pharmaceutical sales[7] - The company reported a significant increase of 230.04% in receivables financing, totaling ¥190,902,628.03, attributed to increased bank acceptance bill settlements[7] - Accounts receivable rose significantly to CNY 6.53 billion, up from CNY 5.02 billion, marking an increase of approximately 30.1%[21] Government Subsidies and Investments - The deferred income increased by 994.59% to ¥94,680,366.15, mainly due to government subsidies received related to projects[8] - The company received a total of 86.8 million yuan in government subsidies for its medical logistics project, with all funds received by September 30, 2021[17] - Investment income received increased by 2018.58% to 307,293.78 yuan from 14,504.70 yuan, attributed to higher dividend payments received[11] Operating Expenses - The company experienced a 125.43% rise in operating expenses, totaling ¥16,146,892.45, primarily due to increased charitable donations[10] - The operating costs for the current period were CNY 19.50 billion, compared to CNY 18.14 billion in the previous period, reflecting an increase of about 7.5%[24] Stock Options and Asset Management - A total of 7.2 million restricted stock options were granted under the 2021 incentive plan, with a grant price of 6.08 yuan per share, pending government approval[17] - The company plans to transfer part of its property assets, with a minimum listing price of 96,944,490 yuan, as part of its strategic asset management[16] Other Financial Information - The company incurred a credit impairment loss of CNY -12,118,840.13, slightly higher than CNY -12,081,860.35 in the previous year[26] - The third quarter report was not audited, indicating that the figures presented are subject to further verification[35]